Publications by authors named "Jean-Claude Ongagna"

9 Publications

  • Page 1 of 1

Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.

Mult Scler 2020 Jul 9:1352458520936239. Epub 2020 Jul 9.

Department of Neurology, Centre Hospitalier Universitaire de Lille, Lille, France/Department of Neuroradiology, Centre Hospitalier Universitaire de Lille, Lille, France.

View Article and Find Full Text PDF
July 2020

Ozone, NO and PM are associated with the occurrence of multiple sclerosis relapses. Evidence from seasonal multi-pollutant analyses.

Environ Res 2018 05 6;163:43-52. Epub 2018 Feb 6.

METIS Department, EHESP French School of Public Health, Sorbonne Paris Cité, 15 avenue du Professeur 6 Léon-Bernard - CS 74312, 35043 Rennes, France; INSERM CIC-P 1414, CHU of Rennes, 2 Rue Henri le Guilloux, 35000 Rennes, France; EA 7449 REPERES, EHESP French School of Public Health, Sorbonne Paris Cité - University of Rennes 1, Rennes, France. Electronic address:

View Article and Find Full Text PDF
May 2018

Air pollution by particulate matter PM may trigger multiple sclerosis relapses.

Environ Res 2017 07 11;156:404-410. Epub 2017 Apr 11.

METIS Department, EA 7449 REPERES, EHESP French School of Public Health, Sorbonne Paris Cité, 15 avenue du Professeur Léon-Bernard - CS 74312, 35043 Rennes, France; INSERM CIC-P 1414, CHU of Rennes, 2 Rue Henri le Guilloux, 35000 Rennes, France. Electronic address:

View Article and Find Full Text PDF
July 2017

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Neurology 2016 12 4;87(23):2491-2494. Epub 2016 Nov 4.

From the CHU Toulouse Purpan (B.P., F.B., D.B., D.A.-P., D.B.), Pôle Neurosciences; INSERM U1043-CNRS UMR 5282 (B.P., F.B., D.B.), Université Toulouse III, Centre de Physiopathologie Toulouse Purpan, France; University of Münster (N.S., T.S.-H., H.W.), Germany; University of Lille (O.O., H.Z., P.V.); Hôpital Civil (J.-C. Ongagna, J.d.S.), Strasbourg; CHU Pellegrin (B.B., J.-C. Ouallet), Bordeaux; CHU Nancy (M.D., S.P.); CHU Caen (G.D., N.D.); CH St Vincent (P.H.), GHICL, Lille; CHU Reims (A.T.); CHU Montpellier (P.L.); CHU Nîmes (G.C., W.C., O.C.); CHRU Clermont Ferrand (P.C.); CHU Besançon (E.B.); Aix Marseille University (J.P., A.R.), APHM, CHU Timone, Marseille; CHU Nantes (D.L., S.W.); CHU Grenoble (E.T.); CHU Dijon (T.M., A.F.); CHU Lyon (S.V.), Bron; Hôpital de la Salpêtrière (C.P.), Paris, France; Centre d'Esclerosi Múltiple de Catalunya (CEMCAT) (M.C.), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and CHU Nice (C.L.-F.), France.

View Article and Find Full Text PDF
December 2016

Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy.

J Neurol 2012 Nov 12;259(11):2293-8. Epub 2012 Apr 12.

Department of Neurology, University Hospital of Lille, Université Lille Nord de France, Hôpital Roger Salengro, 1 rue Emile Laine, 59037, Lille Cedex, France.

View Article and Find Full Text PDF
November 2012

Markers for risk of type 1 diabetes in relatives of Alsacian patients with type 1 diabetes.

Int J Exp Diabetes Res 2002 ;3(1):1-9

Centre Européen d'Etude du Diabète-Hĵpitaux Universitaires de Strasbourg.

View Article and Find Full Text PDF
September 2002